Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapies

With Big Pharma backing and helmed by a research veteran, Nuvig has exited stealth mode with the bold aim of fundamentally transforming autoimmune disease treatment.

The company is based on a “new understanding of how the immune system naturally equilibrates itself,” Nuvig said in a May 11 announcement. This knowledge has allowed the company to develop protein therapeutics that have been genetically engineered to activate a class of immune-regulatory receptors that rebalance immune function following inflammation.